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Spray-drying process preserves the 
protective capacity of a breast milk-
derived Bifidobacterium lactis strain 
on acute and chronic colitis in mice
Patricia Burns1,2, Jeanne Alard1, Jiri Hrdỳ1,†, Denise Boutillier1, Roxana Páez3, 
Jorge Reinheimer2, Bruno Pot1, Gabriel Vinderola2 & Corinne Grangette1
Gut microbiota dysbiosis plays a central role in the development and perpetuation of chronic 
inflammation in inflammatory bowel disease (IBD) and therefore is key target for interventions with 
high quality and functional probiotics. The local production of stable probiotic formulations at limited 
cost is considered an advantage as it reduces transportation cost and time, thereby increasing the 
effective period at the consumer side. In the present study, we compared the anti-inflammatory 
capacities of the Bifidobacterium animalis subsp. lactis (B. lactis) INL1, a probiotic strain isolated in 
Argentina from human breast milk, with the commercial strain B. animalis subsp. lactis BB12. The 
impact of spray-drying, a low-cost alternative of bacterial dehydration, on the functionality of both 
bifidobacteria was also investigated. We showed for both bacteria that the spray-drying process did not 
impact on bacterial survival nor on their protective capacities against acute and chronic colitis in mice, 
opening future perspectives for the use of strain INL1 in populations with IBD.
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic 
relapsing inflammatory disorder. Although the exact pathophysiology of the disease is unknown, the current 
paradigm is multifactorial and involves a dysregulation of the mucosal immune response towards the gut micro-
biota in a genetically susceptible host1. At present, effective therapeutic management of IBD is lacking: 25–30% 
of patients fail to respond to current biologics and/or to immunosuppressive drugs, resulting in accumulation of 
adverse events, including malignancies, and leading to increased levels of opportunistic infections2. Therefore 
new strategies for treating this disease are imperative. While the microbiota is a determinant of normal gut func-
tion and immunity, there is increasing evidence that impaired microbiota composition (dysbiosis) plays a crucial 
role in the onset and maintenance of active IBD3,4. Therefore targeting this dysbiosis is potentially crucial in the 
management of the disease.
Probiotics are defined as microorganisms that, when administered in adequate amounts, can confer a health 
benefit on the host (FAO/WHO5), revisited by an expert panel of the International Scientific Association for 
Probiotics and Prebiotics (ISAPP) in 20136. Probiotics have emerged as a new potential therapeutic strategy 
in IBD, notably for patients wishing to use “natural and safe” approaches. Following positive results obtained 
with different animal models of colitis, clinical intervention studies indeed showed beneficial activities of 
some probiotics in patients suffering from pouchitis or ulcerative colitis7. Their protective effects were clearly 
strain-depended, and several well-characterized probiotic strains failed to fulfil the expected clinical outcome, in 
particular in patients suffering from Crohn’s disease (CD)8. We have previously shown that protection by lacto-
bacilli and bifidobacteria against TNBS (trinitrobenzene sulfonic acid)-induced colitis in mice was strain-specific 
and correlated well with the in vitro immunomodulatory properties of the strains9. Strains inducing higher levels 
of the anti-inflammatory cytokine IL-10 and lower levels of the pro-Th1 cytokines IL-12 and IFNγ after in vitro 
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stimulation of human peripheral mononuclear cells (PBMC), offered the best protection in the in vivo colitis 
model used. In contrast, strains inducing a low IL-10/IL-12 cytokine ratio on human PBMC’s could not signifi-
cantly attenuate colitis symptoms in mice9.
Gut microbiota composition depends on dietary habits and lifestyle, and as such the microbiome compo-
sition of people from different regions can be different10. This offers local source of beneficial microbes with a 
decrease in the relative costs, thus particularly benefiting subpopulations in the emerging countries11. Here we 
evaluate the anti-inflammatory effects of the strain Bifidobacterium animalis subsp. lactis (B. lactis) INL1, isolated 
in Argentina from human breast milk and shown before to display technological12 and functional properties in 
mice13,14 that make it a potential candidate for probiotic application in IBD.
An increasing demand for probiotics is challenging the industry to produce high amounts of viable cul-
tures in stable forms15. Industrial manufacturing processes can significantly alter the structural and functional 
properties of live microorganisms16. While freeze-drying is most commonly used, other drying processes for 
microorganism preservation have been tested. Spray drying is a low-cost alternative to freeze-drying because 
it is relatively inexpensive and allows the production of large amounts of dried cells in a continuous process17. 
Particularly in Argentina, many medium to large-size dairy industries possess spray drying infrastructures, which 
could be exploited for the production of spray dried probiotics. However, spray drying implies somewhat harsher 
conditions than freeze drying, which might cause membrane damage and cell inactivation. Therefore, the fea-
sibility to apply spray-drying to probiotics will depend on the technological conditions applied and it is antic-
ipated that the impact on the strain functionality might be strain dependent. We thus decided to compare the 
anti-inflammatory capacities of the Argentinian strain B. animalis subsp. lactis (B. lactis) INL1 and B. lactis BB12, 
largely described as beneficial in a number of inflammatory conditions18 and study the impact of spray-drying on 
the anti-inflammatory functionality of both strains.
Results
The spray-drying did not decrease bacterial survival. Fresh cultures of bididobacteria were spray-
dried in 20% (w/v) skim milk (constant inlet air temperature of 137.5 ± 3.5 °C, an outlet temperature of 
82.5 ± 7.8 °C and a flux of 600 l/h were used). The mean value of moisture of the powders obtained after spray dry-
ing was 3.89% ± 0.09 and 4.22% ± 1.59 (wt/wt) for B. lactis INL1 and B. lactis BB12, respectively. Both B. animalis 
subsp. lactis strains INL1 and BB12 exhibited a satisfactory resistance capacity to spray drying, with a respective 
survival rate of 97.36 and 98.12% (Table 1). No significant differences in cell counts were observed before and 
after spray drying.
The immunomodulation capacities of B. animalis subsp. lactis INL1 and BB12 strain are simi-
lar and not affected by spray-drying. The capacity of both bifidobacterial strains to induce the release 
of cytokines after in vitro stimulation of human PBMC’s, was compared (Fig. 1). The cytokine profile observed 
for INL1 was similar to that of BB12. Indeed both strains were good inducers of the anti-inflammatory cytokine 
IL-10, while they induced low levels of the pro-Th1 cytokines (IL-12 and IFNγ ), leading to a high IL-10/IL-12 
ratio in comparison to e.g. L. acidophilus NCFM, selected for its strong capacity to induce pro-Th1 cytokines9,19. 
Spray drying slightly decreased their capacity to induce IL-10 but both spray-dried bifidobacteria maintained 
their anti-inflammatory profile as highlighted by the IL-10/IL-12 ratio which remained significantly (p < 0.05) 
higher than that of the pro-Th1 L. acidophilus NCFM strain.
B. lactis INL1 and BB12 strains rescued mice from acute colitis and these protective capacities 
were not affected by spray-drying. To compare the in vivo anti-inflammatory capacities of both INL1 
and BB12 strains, we first used a well-established murine model of acute colitis (Fig. 2A), induced by TNBS 
(110 mg/Kg)9,20. As expected, TNBS treatment (after 48 h induction) reduced body weight (by 13%; Fig. 2B) and 
induced a strong colitis, highlighted both by a high macroscopic score (Wallace score of 5.9 ± 0.6, Fig. 2C) as 
well as a high histological score (Ameho score of 5.7 ± 0.2, Fig. 2D,E). Both fresh cultures of B. lactis INL1 and 
BB12 were able to significantly protect mice from colitis, as shown by a strong and significant reduction of both 
macroscopic (p < 0.01, Fig. 2C) and histological (p < 0.001, Fig. 2D,E) scores of inflammation, leading to a pro-
tective effect of 53.8% and 56.8%, respectively. This protective effect was not significantly affected by spray drying 
since both spray-dried strains were also able to reduce the macroscopic (p < 0.001 and 0.01 for INL-1 and BB12, 
respectively) and histological (p < 0.001) scores of inflammation, reaching 61.1% protection for INL1 (Fig. 2). The 
anti-inflammatory capacity of both strains, whether fresh or spray-dried, was confirmed by following the colonic 
mRNA expression of pro-inflammatory cytokines and chemokines, showing a strong and significant (p < 0.05 
and 0.01) downregulation of the gene expression of all the inflammatory markers tested (CXCL2, IL-1β , TNF-α , 
IL-6) in comparison to control TNBS-treated mice. The latter, because of the TNBS treatment exhibited a strong 
Strains
Cell count (log CFU/ml)
Survival rate (%)Before SD After SD
B. lactis INL-1 10.19 ± 0.08 9.92 ± 0.08 97.36 ± 1.44
B. lactis Bb12 10.10 ± 0.07 9.91 ± 0.10 98.12 ± 0.94
Table 1.  Resistance of B. lactis INL-1 and B. lactis BB12 to spray drying in 20% (w/v) skim milk. 
Mean ± SD. No significant differences in cell counts before and after spray drying, according to paired t-test 
(p > 0.05).
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upregulation of these pro-inflammatory genes (Fig. 3) in comparison to control healthy mice that received only 
skim milk but not challenged with TNBS (normalized to 1).
The anti-inflammatory capacity of fresh and spray-dried forms of B. lactis INL1 and BB12 
strains was confirmed in a model of chronic colitis. The model of chronic TNBS inflammation used in 
this study involves the induction of a low grade, subclinical inflammatory status, mimicking the chronic nature 
of inflammation in IBD21. Chronic low-grade inflammation was induced in mice by the administration of 3 sub-
clinical, but increasing doses of TNBS (Fig. 4A). This led to a moderate body weight loss (9.8% ± 2.3, Fig. 4B), 
decrease of colon length (7.5 ± 0.2 cm versus 9.5 ± 0.5 cm for healthy control mice, Fig. 4C), and the induction 
of a mild macroscopic (Wallace score of 3.1 ± 0.5; Fig. 4D) and histological (1.9 ± 0.8; Fig. 4E,F) inflammation 
scores, as compared to the acute colitis model. The chronic colitis model also led to a significant upregulation 
of inflammatory gene expressions (Fig. 5) that were, however, less severe than those observed for acute colitis 
(Fig. 3). As for acute colitis, both B. lactis strains were able to counteract the inflammation status, showing sig-
nificant (p < 0.05 or 0.01) decrease in weight loss and macroscopic score of inflammation, significant increase 
(p < 0.05 or 0.01) of colon length and a slight decrease of the histological score of inflammation (Fig. 5), in com-
parison to TNBS-treated control animals. Both strains were also able to significantly (p < 0.05 and 0.01) decrease, 
with the same efficiency, the expression of pro-inflammatory genes (cxcl2, Il1b and il6). In this model we also 
checked the capacity of the probiotics to induce the expression of foxp3 which is a marker of regulatory T cells. 
We indeed observed a significant (p < 0.05) increase of the expression of this gene in all probiotic-treated animals 
in comparison to TNBS control mice (Fig. 5). Again, spray-dried and fresh bacteria displayed the same efficacy 
in counteracting chronic colitis.
Figure 1. Impact of the drying process on the immunomodulatory potential of B. lactis INL1 and BB12. 
Peripheral blood mononuclear cells (PBMCs, 5 donors per condition) were stimulated in vitro at a ratio of 10:1 
(bacteria/cells) with fresh or spray-dried B. lactis INL1 and BB12 and by fresh L. acidophilus strain NCFM (two 
wells per donor). Results indicated levels of IL-10, IL-12 and IFNγ released by bacteria-stimulated and control 
human PBMCs for 24 hours and levels of IL-10/IL-12 ratio (mean ± SEM of 5 independent experiments). 
The indications *or # meaning p < 0.05, refer to the comparison of bifidobacteria-stimulated PBMCs versus 
untreated cells (*medium control) or versus L. acidophilus-stimulated PBMC (# L. acidophilus effect), 
respectively.
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Discussion
The increased understanding of the interactions between the gut microbiota and the host immune system has 
raised the interest towards a targeted modulation of intestinal bacterial communities as a novel potential therapy 
in IBD. Similar to the findings in animals, several studies showed a significant alteration of the microbiota in IBD 
patients22. Significantly lower counts of Faecalibacterium prausnitzii but also of bifidobacteria were found in the 
rectal biopsies of patients with UC, as compared to healthy patients23,24. While promising outcomes have been 
observed after gut microbiota modulation through probiotic supplementations in UC patients25–27, disappointing 
results were obtained for CD patients (see systematic review7). It is noteworthy that the effects are considered 
Figure 2. Fresh and spray-dried B. lactis INL1 and BB12 alleviated severity of acute TNBS-induced 
colitis in mice. (A) Experimental protocol used for the mouse model of acute colitis induced by intrarectal 
administration of 110 mg/Kg of TNBS, while control healthy mice received only 50% EtOH. Mice were treated 
with the probiotics by daily intragastric administration (2 × 108 CFU in 200 μ l 20% (w/v) skim milk) or by 20% 
(w/v) skim milk (control healthy mice and control TNBS) for five consecutive days before colitis induction 
(intrarectal administration of TNBS at 110 mg/Kg) and 1 day after TNBS administration. (B) Body weight loss 
(as a percentage of the initial weight at the day of colitis induction). (C) Macroscopic evaluation of colonic 
inflammation (Wallace score). Percentages of protection are indicated above each bar (D) Histologic evaluation 
of colonic inflammation (Ameho score). (E) Representative histological sections (stained by May Grünwald 
Giemsa, 100X magnification) of mice treated with skim milk and administrated (Control TNBS) or not (heathy 
mice) with TNBS, and mice that were treated with fresh or spray-dried B. lactis INL1 and BB12 before and one 
day after TNBS administration. The data represent the mean ± SEM of 10 mice per group of a representative 
experiment. Two different experiments were performed. **p < 0.01 or ***p < 0.001 versus the TNBS control 
group. For histology, 5 sections of each mouse (n = 10 per experimental group) were analyzed.
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strain-specific and more studies are needed to understand the underlying mechanisms of action prior to their 
prophylactic or therapeutic use in IBD patients7,28.
The selection of probiotic strains should therefore be driven by the needs identified at the level of the host 
(infection, inflammation, barrier deficiency) and the in vitro and in vivo established immunological, microbio-
logical and/or metabolic effects of the microorganisms to be considered. In the above philosophy, it is very impor-
tant that further research is conducted in order to better understand the interactions between the gut microbiota 
and the host, in states of health as well as in states of dysbiosis. Bifidobacteria are normal residents of the human 
intestine, commonly found in the infant gut and particularly enriched in the intestine of breastfed infants29. Their 
role early in life is to promote a tolerogenic immune system in the neonate, in order to reverse the Th2 skewed 
immune system inherited from the pregnant mother30,31. The latter is promoted by several mechanisms, includ-
ing the promotion and delivery of bifidobacteria to the newborn via breast milk32. Breast milk has shown to be 
a continuous source of commensal, potentially probiotic, bacteria for the infant gut. Bifidobacteria in particular 
are known to play a crucial role in the prevention of a variety of immune-mediated diseases such as allergy and 
IBD29,33.
In the present study, we thus evaluated B. animalis subsp. lactis INL1, a strain isolated from human breast 
milk as a potential candidate for probiotic application in patients suffering from IBD. We notably compared its 
anti-inflammatory capacities to the well-known probiotic strain B. lactis BB12, which is largely recognized for its 
probiotic properties including its anti-inflammatory capacity34. Moreover, we evaluated in both strains the impact 
of spray-drying process on their anti-inflammatory functionality. Spray-drying is an economically interesting 
process for the preparation of industrial quantities of viable microorganisms, the cost of which is only 12–20% 
of the cost of freeze drying35. While currently mostly used to prepare food additives, it recently received con-
siderable interest for the production of probiotics. Preliminary experience, however, showed that the successful 
application of the process is strain-dependent17,36, mainly because of the high processing temperatures used17. 
High temperatures may potentially reduce strain viability and could lead to important variations in bacterial 
hydrophobicity and immunomodulation properties.
We first showed that for both strains investigated, the spray drying process in a 20% (w/v) skim milk car-
rier, had no deleterious impact on bacterial survival, confirming earlier observations for Bifidobacterium species, 
which were shown to have a high resistance to spray drying37. Moreover, we found that both B. lactis strains 
Figure 3. Fresh or spray-dried B. lactis INL1 and BB12 dampened colonic inflammatory gene expression 
in the acute TNBS-induced colitis model. Gene expression of Cxcl2, il1b, tnfa, il6 in colonic samples harvested 
two days after colitis induction was assessed by real time qPCR. Values are expressed as the relative mRNA 
levels compared with colons from healthy mice. Data represent mean values of 10 animals ± SEM. *p < 0.05; 
**p < 0.01, in comparison to TNBS control samples.
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exhibited a similar in vitro anti-inflammatory cytokine induction profile (high IL-10 versus IL-12 ratio), and 
that this immunomodulation capacity was not affected by the spray-drying process. Laconelli et al.38 recently 
reported that the effects on cell functionality of dehydration treatment are not directly linked to cell survival, and 
they illustrated that each bacterial strain had a specific sensitivity to the three different drying processes used. 
Spray-drying performed extremely well in terms of viability and functionality, mainly because it decreased the in 
vitro induction of pro-inflammatory/proTh1 cytokines. In the present study with bifidobacteria, spray-drying did 
not significantly impact their capacity to induce IL-10 nor the pro-Th1 cytokines IL-12 and IFNγ .
The anti-inflammatory potential of both B. lactis strains was further confirmed using a standardized acute 
TNBS-induced colitis model9,20. Both B. lactis strains were able to rescue mice against acute colitis and were also 
able to limit the inflammation levels as confirmed by the strong decrease of gene expression for pro-inflammatory 
cytokines.
Figure 4. Fresh and spray-dried B. lactis INL1 and BB12 rescued mice from chronic TNBS-induced colitis. 
(A) Experimental protocol used for the mouse model of chronic colitis induced by intrarectal administrations 
of 3 increasing doses of TNBS (25 mg/kg, day 0; 37.5 mg/kg, day 7 and 80 mg/kg, day 14), at one week interval, 
while control healthy mice received only 50% EtOH. Mice were treated with the probiotics by daily intragastric 
administration [2 × 108 CFU in 200 μ l 20% (w/v) skim milk) or by 20% (w/v) skim milk (control healthy 
mice and control TNBS)] every day during colitis induction (from D0 to D15). (B) Body weight loss (as a 
percentage of the initial weight). (C) Colon length at sacrifice (Day 16). (D) Macroscopic evaluation of colonic 
inflammation (Wallace score). Percentages of protection are indicated above each bar (E) Histologic evaluation 
of colonic inflammation (Ameho score). (F) Representative histological sections (stained by May-Grünwald-
Giemsa, 100X magnification) of mice treated with skim milk and administrated (Control TNBS) or not (heathy 
mice) with TNBS, and mice that were treated with fresh or spray-dried B. lactis INL1 and BB12 during all the 
experiment. The data represent the mean ± SEM of 10 mice per group of a representative experiment. Two 
different experiments were performed. *p < 0.05, **p < 0.01 versus the TNBS control group.
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We also set up a model of chronic colitis, induced by the administration of 3 subclinical but increasing doses 
of TNBS. We observed an induction of low grade, subclinical inflammation, with mild macro- or microscopic 
damages and lower pro-inflammatory cytokine induction, as compared to the acute TNBS model. Therefore 
the chronic model is thought to better mimic the chronic nature of inflammation in IBD patients. Both B. lactis 
strains were again able to rescue mice from chronic colitis, with similar levels of protection as observed in the 
acute colitis model, and were also able to limit inflammation levels, as measured by cytokine gene expression. 
Regulatory T (Treg) cells are known to play a critical role in the control of inflammatory response. Transcriptional 
factor FoxP3 serves as a lineage specification factor of these cells39. In the chronic model of colitis, we showed that 
both B. lactis strains increased the expression of foxp3, suggesting that a desired T-regulatory cell response could 
be involved in the protective effect.
Importantly, the bacterial functionalities of both strains were not affected by spray-drying. Spray-dried 
bacteria were able to decrease the macroscopic and histologic scores of inflammation, and dampened the 
pro-inflammatory cytokine expression. Spray-dried bifidobacteria were also able to upregulate foxp3 gene expres-
sion at the same level as fresh cultures, indicating that spray-drying did not alleviate their immune-regulatory 
capacities. This confirms previous studies performed with probiotic lactobacilli which showed that spray-drying 
did not impact e.g. the induction of immunoglobulin A (IgA)-producing cells in mice36. Therefore spray-drying 
appears to be an interesting process for the stabilization of probiotic bifidobacteria.
In conclusion, these results provide further evidence of the probiotic potential of the B. lactis INL1 strain, and 
particularly for an application in the attenuation of gut inflammation. Moreover, since bacterial functionalities were 
not affected by spray-drying, this preservation process appears to be an interesting process for the stabilization of 
this strain. Based on our data, it can be concluded that the strain INL1 has the potential to be explored as prospective 
functional therapy to manage IBD. Further studies should be conducted to investigate the mechanism of action of 
the bacterium and to establish its clinical efficacy in well-designed double-blind placebo-controlled human trials.
Methods
Microorganisms and growth conditions. B. animalis subsp. lactis INL1, whose functional and techno-
logical properties were previously reported12–14, was used in this study and compared to the commercial strain 
Figure 5. Fresh or spray-dried B. lactis INL1 and BB12 abrogated colonic inflammatory gene expression 
and increased foxp3 in the chronic TNBS-induced colitis model. Gene expression of Cxcl2, il1b, il6 and foxp3 
in colonic samples harvested two days after the last TNBS administration (D16) was assessed by real time qPCR. 
Values are expressed as the relative mRNA levels compared with colons from healthy mice. Data represent mean 
values of 10 animals ± SEM. *p < 0.05; **p < 0.01, in comparison to TNBS control samples.
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B. animalis subsp. lactis BB12. L. acidophilus NCFM kindly provided by DuPontTM Danisco (Madison, WI, USA). 
was also grown overnight at 37 °C in de Man, Rogosa and Sharpe broth (MRS, Difco, Detroit, USA) and used as 
pro-Th1 control strain9. Bifidobacteria were cultured overnight at 37 °C in anaerobic condition (GENbag anaer, 
Biomérieux, France), in MRS supplemented with 0.1% (w/v) L-cysteine hydrochloride (Sigma), washed twice 
in sterile PBS and resuspended in PBS for in vitro studies and in 20% (w/v) skim milk for in vivo experiments. 
Spray-dried cultures were resuspended in distilled water to a 20% (w/v) of total solids, in order to have fresh and 
spray-dried cells resuspended in the same medium.
Spray drying in skim milk. Overnight cultures of both bifidobacteria strains in MRS broth with 0.1% (w/v) 
L-cysteine hydrochloride were harvested (6000 × g, 15 min, 5 °C), washed twice with PBS and re-suspended in 
20% (w/v) skim milk. Cell suspensions were spray-dried on a laboratory scale spray-dryer (Buchi mini spray 
dryer model B290, Flawil, Switzerland). A constant inlet air temperature of 137.5 ± 3.5 °C, an outlet temperature 
of 82.5 ± 7.8 °C and a flux of 600 l/h were used. Cell suspensions were atomized and sprayed into the drying 
chamber by using a two-fluid nozzle. The product dried almost instantaneously and the residence time was neg-
ligible. Three independent replicates were performed for each strain. Spray dried powders were vacuum sealed 
in individual samples of 10 g. Residual moisture (% wt/wt) was determined in triplicate at 101 ± 1 °C (FIL-IDF 
26 A: 199340). Cell counts of bifidobacteria were performed before and after spray drying on MRS with 0.1% (w/v) 
L-cysteine hydrochloride agar (37 °C, 48 h anaerobic incubation).
Bacterial enumeration. Bifidobacteria suspensions were serially diluted in PBS buffer, plated on MRS agar 
supplemented with 0.1% (w/v) L-cysteine hydrochloride and grown under anaerobic condition (GENbag anaer, 
Biomérieux, France) at 37 °C. Colonies were counted after 48 h of incubation.
In vitro immunomodulation assays. Blood samples were obtained from five healthy informed donors. All 
experimental protocols were approved by our institution committees (INSERM, CNRS and Institut Pasteur de 
Lille) in accordance with relevant guidelines and regulations. Blood sampling from healthy informed donors 
were done upon approved agreement of volunteers (signed consents) by authorized staff in accordance with 
the abovementioned committees, i.e. (INSERM, CNRS and Institut Pasteur de Lille). Peripheral blood mononu-
clear cells (PBMCs) were isolated from the blood as described before9. Briefly, after Ficoll gradient centrifuga-
tion (Pharmacia, Stockholm, Sweden), mononuclear cells were collected, washed in RPMI-1640 medium (Life 
Technologies, Ghent, Belgium), and adjusted to 2 × 106 cells per ml in RPMI supplemented with gentamicin 
(150 μ g/ml), glutamine (2 mM), and 10% fetal calf serum (Gibco). PBMCs (two wells per donors) were stimulated 
with phosphate-buffered saline or bacteria (fresh cultured or spray dried bacteria at a bacterium-to-cell ratio of 
10:1) for 24 h at 37 °C with 5% CO2. The supernatants were collected and stored at − 20 °C until cytokine meas-
urements performed using R&D Duoset ELISA kits (R&D, Minneapolis, MN, USA). ELISA was performed in 
duplicate for each sample.
Experimental TNBS-induced colitis models and study design. Female BALB/c ByJ mice (7–8 
weeks old) were purchased from Charles River Laboratories (L’Arbresle, France) and were maintained under 
specific pathogen-free conditions. Animal experiments were performed in an accredited establishment (number 
A59107; animal facility of the Institut Pasteur de Lille, France) and carried out in accordance with the guide-
lines of laboratory animal care published by the French Ethical Committee and the rules of the European Union 
Normative (number 86/609/EEC). All the studies were approved by the local investigational ethics review board 
(Nord-Pas-de-Calais CEEA N°75, Lille, France; protocol reference numbers 192009 R). The animal experiments 
also complied with French legislation (Government Act 87–848) and the European Communities Amendment of 
Cruelty to Animals Act 1976. Before experimentation, animals were provided a one week acclimation period and 
were given ad libitum access to regular mouse chow and water.
A standardized murine TNBS colitis model was used to induce acute levels of inflammation in mice (Fig. 2A). 
Briefly, mice (n = 10 per each experimental group) were randomly co-housed in two cages per group (n = 5/cage) 
and the experiment started after one week acclimation. The anti-inflammatory properties of the bifidobacteria 
were evaluated by the intra-gastric administration of live bacteria (2 × 108 CFU of freshly cultured or spray-dried 
bacteria in 20% (w/v) skim milk) or 20% (w/v) skim milk alone (for the control healthy or TNBS-treated mice) 
once daily, for five consecutive days before colitis induction and 1 day after the TNBS administration. For acute 
colitis induction, mice were anesthetized and received an intrarectal administration of a 50 μ l solution of the hap-
ten reagent TNBS (Sigma-Aldrich, France) dissolved in 0.9% NaCl/ethanol (50/50 v/v) at a final concentration of 
110 mg/Kg, while control healthy mice received only 50% EtOH.
The chronic model of colitis was performed by administration of 3 increasing doses of TNBS with one week 
interval as described in Fig. 4A (n = 10 mice per each experimental group randomly co-housed in two cages 
per group; n = 5/ cage). Briefly, anesthetized mice received intrarectally 50 μ l solution of TNBS (Sigma-Aldrich, 
France) at a dose of 25 mg/Kg (day 0), 37.5 mg/Kg (day 7) and 80 mg/Kg (day 14), dissolved in 0.9% NaCl/ethanol 
(50/50 v/v), while control healthy mice received only 50% EtOH. The anti-inflammatory properties of the bifido-
bacteria were evaluated by the daily intra-gastric administration of live bacteria (2 × 108 CFU of freshly cultured 
or spray-dried bacteria in 20% (w/v) skim milk) or 20% (w/v) skim milk (for the TNBS control or healthy control 
mice) every day during all the experimental procedure (from D0 to D15).
Colons were removed at sacrifice (48 h after the last TNBS administration), washed and opened. Inflammation 
grading was performed blindly using the Wallace scoring method, reflecting both the intensity of inflammation 
and the extent of the lesions41. Protection was calculated using the following formula: 100 x [(mean score of TNBS 
group – mean score of experimental group)/mean score of TNBS group]. Histological analysis was carried out on 
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May-Grünwald Giemsa stained 5 μ m tissue sections from colon samples (5 sections per mice) fixed in 4% forma-
lin, embedded in paraffin and blindly scored according to the Ameho scoring method42. For RT-PCR analysis, a 
part of the colon corresponding to the inflamed region was cleaned from fecal material and stored in RNA-later® 
buffer (Ambion, Life Technologies, Austin, TX, USA) at –80 °C until RNA extraction.
RNA extraction and qRT-PCR. Tissue samples were homogenized using Lysing Matrix D (MPbio). 
Total RNA was extracted using Macherey-Nagel NucleoSpin RNAII isolation kit according to the manufac-
turer’s recommendation. Quantity and quality of RNA were checked by nanodrop (260/280 nm, 260/230 nm). 
260/280 ratio was higher than 1.95 in all samples. RNA (1 μ g) was reverse-transcribed using the High capac-
ity cDNA reverse transcription kit (Applied BiosystemsTM, Foster City, CA, USA). Real-time quantitative 
PCR (RT-qPCR) was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems) on the 
ABI-ViiA7 Real Time PCR system. The forward and reverse primers used in the study were, respectively as 
follows: b-actine: 5′ - CTAAGGCCAACCGTGAAAAC -3′ and 5′ - ACCAGAGGCATACAGGGACA-3′ ; il1b: 
5′ -TTGACGGACCCCAAAAGATG-3′ and 5′ -AGAAGGTGCTCATGTCCTCA-3′; tnfa: 5′-CCCTCACA 
CTCAGATCATCTTCTC-3′ , and 5′-GGCTACAGGCTTGTCACTCG-3′; cxcl2: 5′-CAAAAGATACT 
GAACAAAGGCAA-3′  and 5′-TCAGGTACGATCCAGGCTTCC-3′ ; il6: 5′-AGCCAGAGTCCTT 
CAGAGAGATAC-3′ and 5′-AATTGGATGGTCTTGGTCCTTAGC-3′ ; foxp3: 5-TCCTTCCCAGAGTTC 
TTCCA-3′ and 5′ -AAGTAGGCGAACATGCGAGT-3′ . The 2−Δ(ΔCT) method was used to normalize gene expres-
sion levels. Relative mRNA levels (2−Δ(ΔCT)) were determined by comparing 1) the PCR cycle thresholds (Ct) for 
the gene of interest and the housekeeping gene Actb (Δ Ct) and 2) Δ Ct values for treated and healthy control 
animal groups (Δ Δ Ct).
Statistics. GraphPad Prism was employed for graph preparation and statistical evaluation. Differences 
between groups were assessed using ANOVA, followed by nonparametric Mann-Whitney test. Data with 
p value ≤ 0.05 were considered to be significant.
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